Impact of age on cardiovascular risk: implications for cardiovascular disease management

Kannel, 1971, Serum cholesterol, lipoproteins, and the risk of coronary heart disease. The Framingham Study, Ann. Intern. Med., 74, 1, 10.7326/0003-4819-74-1-1 Downs, 1998, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study, JAMA, 279, 1615, 10.1001/jama.279.20.1615 Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration. Lancet 1995;346:1647–53. Shepherd, 1995, Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group, N. Engl. J. Med., 333, 1301, 10.1056/NEJM199511163332001 Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383–9. Pfeffer, 1995, Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. CARE Investigators, Am. J. Cardiol., 76, 98C, 10.1016/S0002-9149(99)80478-0 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339:1349–57. Isomaa, 2001, Cardiovascular morbidity and mortality associated with the metabolic syndrome, Diab. Care, 24, 683, 10.2337/diacare.24.4.683 Martin, 1986, Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men, Lancet, 2, 933, 10.1016/S0140-6736(86)90597-0 Casiglia, 2003, Total cholesterol and mortality in the elderly, J. Intern. Med., 254, 353, 10.1046/j.1365-2796.2003.01200.x Goldstein, 1975, Lipoprotein receptors, cholesterol metabolism, and atherosclerosis, Arch. Pathol., 99, 181 Libby, 2002, Stabilization of atherosclerotic plaques: new mechanisms and clinical targets, Nat. Med., 8, 1257, 10.1038/nm1102-1257 Gordon, 1977, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study, Am. J. Med., 62, 707, 10.1016/0002-9343(77)90874-9 Jousilahti, 1998, Serum cholesterol distribution and coronary heart disease risk: observations and predictions among middle-aged population in eastern Finland, Circulation, 97, 1087, 10.1161/01.CIR.97.11.1087 Jousilahti, 1998, Role of known risk factors in explaining the difference in the risk of coronary heart disease between eastern and southwestern Finland, Ann. Med., 30, 481, 10.3109/07853899809002490 Aronow, 1996, Risk factors for new coronary events in a large cohort of very elderly patients with and without coronary artery disease, Am. J. Cardiol., 77, 864, 10.1016/S0002-9149(97)89183-7 Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X Austin, 1991, Plasma triglyceride and coronary heart disease, Arterioscler. Thromb., 11, 2, 10.1161/01.ATV.11.1.2 Walldius, 2001, High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study, Lancet, 358, 2026, 10.1016/S0140-6736(01)07098-2 Bots, 1996, Low diastolic blood pressure and atherosclerosis in elderly subjects. The Rotterdam Study, Arch. Intern. Med., 156, 843, 10.1001/archinte.1996.00440080029004 Lewington, 2002, Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies, Lancet, 360, 1903, 10.1016/S0140-6736(02)11911-8 Ezenwaka, 2002, Differences in cardiovascular disease risk factors in elderly and younger patients with type 2 diabetes in the West Indies, Singapore Med. J., 43, 497 Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diab Care 2003;26:688–96. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic criteria in Europe. Lancet 1999;354:617–21. Consequences of the new diagnostic criteria for diabetes in older men and women. DECODE Study. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Diab Care 1999;22:1667–71. Balkau, 2000, The DECODE study. Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe, Diab. Metab., 26, 282 Haffner, 1990, Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes?, JAMA, 263, 2893, 10.1001/jama.1990.03440210043030 Grundy, 1999, Hypertriglyceridemia, insulin resistance, and the metabolic syndrome, Am. J. Cardiol., 83, 25F, 10.1016/S0002-9149(99)00211-8 Balkau, 1999, New diagnostic criteria for diabetes and mortality in older adults, Lancet, 353, 68, 10.1016/S0140-6736(05)74840-6 Lakka, 2002, The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 288, 2709, 10.1001/jama.288.21.2709 Strandberg, 2003, Possibilities of multifactorial cardiovascular disease prevention in patients aged 75 and older: a randomized controlled trial: Drugs and Evidence Based Medicine in the Elderly (DEBATE) Study, Eur. Heart J., 24, 1216, 10.1016/S0195-668X(03)00240-9 Durstine, 1994, Effects of exercise training on plasma lipids and lipoproteins, Exerc. Sport Sci. Rev., 22, 477, 10.1249/00003677-199401000-00017 Verissimo, 2002, Effect of physical exercise on lipid metabolism in the elderly, Rev. Port. Cardiol., 21, 1099 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22. Jones P, for the STELLAR Study Group. Statin therapies for elevated lipid levels compared across dose ranges to rosuvastatin: low-density lipoprotein-cholesterol and high-density lipoprotein cholesterol. J Am Coll Cardiol 2003;(Suppl):315–16A. Collins, 2003, MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial, Lancet, 361, 2005, 10.1016/S0140-6736(03)13636-7 Sever, 2003, Lancet, 361, 1149, 10.1016/S0140-6736(03)12948-0 UKPDS Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 1998;317:703–13. Yusuf, 2000, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators, N. Engl. J. Med., 342, 145, 10.1056/NEJM200001203420301 Hansson, 1998, Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group, Lancet, 351, 1755, 10.1016/S0140-6736(98)04311-6 Amery, 1985, Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial, Lancet, 1, 1349, 10.1016/S0140-6736(85)91783-0 Staessen, 1997, Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Lancet, 350, 757, 10.1016/S0140-6736(97)05381-6 Dahlof, 1991, Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension), Lancet, 338, 1281, 10.1016/0140-6736(91)92589-T Bulpitt, 2003, Results of the pilot study for the Hypertension in the Very Elderly Trial, J. Hypertens., 21, 2409, 10.1097/00004872-200312000-00030 Birkenhager, 2000, Effects of antihypertensive treatment on endpoints in the diabetic patients randomized in the Systolic Hypertension in Europe (Syst-Eur) trial, J. Nephrol., 13, 232 The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diab Care 2002;25:2165–71. Tuomilehto, 2001, Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance, N. Engl. J. Med., 344, 1343, 10.1056/NEJM200105033441801 Chiasson, 2002, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial, Lancet, 359, 2072, 10.1016/S0140-6736(02)08905-5 Chiasson, 2003, Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial, JAMA, 290, 486, 10.1001/jama.290.4.486 Qiao, 2001, Diagnostic criteria of glucose intolerance and mortality, Minerva Med., 92, 113 Turner, 1999, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group, JAMA, 281, 2005, 10.1001/jama.281.21.2005 UKPDS Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–53. Manley, 2003, Haemoglobin A1c—a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS), Clin. Chem. Lab. Med., 41, 1182, 10.1515/CCLM.2003.182 Smith U. Pioglitazone: mechanism of action. Int J Clin Pract Suppl 2001;13–8. Buchanan, 2002, Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women, Diabetes, 51, 2796, 10.2337/diabetes.51.9.2796 Ericsson, 1996, Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients, Lancet, 347, 849, 10.1016/S0140-6736(96)91343-4 Frick, 1997, Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group, Circulation, 96, 2137, 10.1161/01.CIR.96.7.2137 Manninen, 1988, Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study, JAMA, 260, 641, 10.1001/jama.1988.03410050061031 Rubins, 1999, Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group, N. Engl. J. Med., 341, 410, 10.1056/NEJM199908053410604 Ljung, 2002, AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats, J. Lipid Res., 43, 1855, 10.1194/jlr.M200127-JLR200 Kivipelto, 2002, Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease, Ann. Intern. Med., 137, 149, 10.7326/0003-4819-137-3-200208060-00006